Cooper Companies delivered its first-ever billion-dollar revenue quarter, with both CooperVision and CooperSurgical reporting record revenues. The company’s performance demonstrated strong growth and margin expansion, driven by successful execution of its multiyear growth strategy.
Summary
Cooper Companies reported impressive Q3 2024 results, with consolidated revenues of $1.003 billion, up 8% year-over-year. CooperVision posted record quarterly revenues of $676 million, up 10% organically, while CooperSurgical achieved record quarterly revenues of $327 million, up 5% organically. Non-GAAP earnings per share grew 14% to $0.96. President and CEO Albert White highlighted the company’s success:
“We couldn’t have reached this milestone without the hard work and dedication of our amazing employees. So a big thank you to the entire Cooper team.”
Main Themes
- Guidance: Full-year consolidated revenue guidance increased to $3.89-$3.91 billion, up 8-8.5% organically
- Competition: Cooper continues to gain market share in the contact lens industry
- New Product Announcements: Launch of upgraded clariti multifocal in the U.S. and new single-handed inserter for PARAGARD
- Market-moving Information: Non-GAAP EPS guidance raised to $3.64-$3.67, up 14-15%
- Economic Outlook: Contact lens and fertility markets remain healthy, with strong demand in focused markets
Insights
CooperVision’s success is driven by its broad product portfolio, ongoing product launches, and strength in premium products. The company’s MyDay and clariti daily silicone hydrogel lenses grew 13%, while Biofinity and Avaira silicone hydrogel FRP lenses grew 11%. MiSight, Cooper’s Myopia management product, posted 50% growth.
CooperSurgical’s fertility business returned to double-digit growth, up 10% in Q3. The company is expanding its leadership position globally through new product launches, accelerated R&D innovation, and geographic expansion.
Market Opportunity
The contact lens market grew approximately 7% in calendar Q2, with Cooper continuing to take share at 10% growth. The fertility market remains strong, supported by macro trends such as women delaying childbirth. The World Health Organization highlights that one in six people globally will be affected by infertility at some point in their lives.
Market Commentary
The contact lens industry is experiencing a shift towards daily silicone hydrogel lenses, particularly in the toric and multifocal segments. Currently, less than half of contact lens wearers are fitted with daily lenses, indicating significant growth potential. The fertility industry is seeing increased patient activity, with clinics upgrading to new technologies and expanding facilities in several markets.
Customer Behaviors
Customers are showing strong demand for premium contact lens products, particularly in the toric and multifocal segments. In the fertility space, clinics are increasing patient activity and upgrading to new technologies. There is growing awareness and adoption of Myopia management solutions, with MiSight gaining traction across all regions.
Capex
While specific capital expenditure figures were not provided, management indicated that CapEx remains elevated due to ongoing capacity expansion initiatives. Free cash flow is expected to improve in the coming year as operating cash flow improves and CapEx moderates.
Economy Insights
Despite economic uncertainties, the contact lens and fertility markets remain healthy. Albert White commented on market demand:
“The state of the market is holding up really well. There’s a little bit of noise every once in a while that we’ll hear, right, you mentioned it with rebates, which is U.S. consumer rebates, relatively small in the grand scheme of things. But if we look at the market, whether it’s the U.S. or we look on a global basis, it remains really healthy.”
Industry Insights
The contact lens industry is experiencing a continued shift towards daily silicone hydrogel lenses, with significant growth potential in the toric and multifocal segments. The fertility industry is benefiting from increased awareness and technological advancements, with clinics expanding and upgrading their facilities.
Key Metrics
Financial Metrics
- Consolidated revenues: $1.003 billion, up 8% year-over-year
- Non-GAAP EPS: $0.96, up 14% year-over-year
- Gross margin: 66.6%, up from 66.1% last year
- Operating margin: 25.5%, up from 23.9% last year
KPIs
- CooperVision revenue growth: 10% organic
- CooperSurgical revenue growth: 5% organic
- MyDay and clariti daily silicone hydrogel lenses growth: 13%
- MiSight growth: 50%
- Fertility business growth: 10%
Competitive Differentiators
- Broadest portfolio of contact lenses in the industry
- Only FDA-approved product for Myopia control (MiSight)
- Leading position in the global fertility industry
- Strong innovation pipeline in both contact lenses and fertility solutions
- Expanding manufacturing capacity to meet growing demand
Key Risks
- Capacity constraints limiting growth potential in certain product lines
- Potential competitive pressures in the IUD market with new entrants
- Currency fluctuations impacting international operations
- Regulatory challenges in obtaining approvals for new products
- Economic uncertainties affecting consumer spending on contact lenses and fertility treatments
Analyst Q&A Focus Areas
Analysts focused on several key areas during the Q&A session:
- Contact lens market dynamics and competitive landscape
- Capacity expansion progress and impact on growth
- Myopia management adoption and future potential
- Fertility business recovery and growth drivers
- PARAGARD performance and competitive positioning
Cooper Companies Summary
Cooper Companies delivered a strong quarter with record revenues and improved margins. The company’s focus on innovation, broad product portfolio, and strategic investments in manufacturing capacity position it well for continued growth. Key areas to watch include the ongoing shift to daily silicone hydrogel lenses, the expansion of the Myopia management market, and the recovery of the fertility business. As Cooper continues to execute its growth strategy, investors should monitor capacity expansion progress, new product launches, and the company’s ability to maintain its market-leading positions in both the contact lens and fertility industries.
Top Takeaways
- Record-breaking quarter with $1.003 billion in revenue, demonstrating strong execution of Cooper’s multiyear growth strategy
- CooperVision continues to gain market share with 10% organic growth, driven by innovative products and expanding capacity
- Fertility business returned to double-digit growth, highlighting Cooper’s strong position in the global fertility market
- Guidance raised for both revenue and earnings, indicating management’s confidence in continued strong performance
- Ongoing shift to daily silicone hydrogel lenses and growing Myopia management market present significant growth opportunities for Cooper Companies
